{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:16:11Z","timestamp":1761513371978},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.lungcan.2013.10.007","type":"journal-article","created":{"date-parts":[[2013,10,19]],"date-time":"2013-10-19T06:45:24Z","timestamp":1382165124000},"page":"73-77","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease"],"prefix":"10.1016","volume":"83","author":[{"given":"Caroline","family":"Mariano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Bosdet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aly","family":"Karsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevin","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janessa J.","family":"Laskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongliang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Melosky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"September (3)","key":"10.1016\/j.lungcan.2013.10.007_bib0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1309\/AJCPFR12WJKCEEZZ","article-title":"Molecular pathology of non-small cell lung cancer: a practical guide","volume":"138","author":"Aisner","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"September (10)","key":"10.1016\/j.lungcan.2013.10.007_bib0010","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"issue":"April (10)","key":"10.1016\/j.lungcan.2013.10.007_bib0015","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J Clin Oncol"},{"issue":"March (3)","key":"10.1016\/j.lungcan.2013.10.007_bib0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"February (2)","key":"10.1016\/j.lungcan.2013.10.007_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"June (25)","key":"10.1016\/j.lungcan.2013.10.007_bib0030","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"August (8)","key":"10.1016\/j.lungcan.2013.10.007_bib0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"issue":"Suppl.","key":"10.1016\/j.lungcan.2013.10.007_bib0040","article-title":"LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations","volume":"30","author":"Chih-Hsin Yang","year":"2012","journal-title":"J Clin Oncol"},{"issue":"December (3)","key":"10.1016\/j.lungcan.2013.10.007_bib0045","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.lungcan.2011.04.008","article-title":"Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials","volume":"74","author":"Ku","year":"2011","journal-title":"Lung Cancer"},{"issue":"September (3)","key":"10.1016\/j.lungcan.2013.10.007_bib0050","doi-asserted-by":"crossref","first-page":"W221","DOI":"10.2214\/AJR.09.3928","article-title":"New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy","volume":"195","author":"Nishino","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"Suppl 8.","key":"10.1016\/j.lungcan.2013.10.007_bib0055","article-title":"Phase III, randomized, open label first-line study of gefitinib vs carboplatin\/paclitaxel in clinically selected patients with advanced small cell lung cancer (IPASS)","volume":"19","author":"Mok","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2013.10.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.41.4557","volume":"30","author":"Zhou","year":"2012","journal-title":"J Clin Oncol"},{"issue":"January (1)","key":"10.1016\/j.lungcan.2013.10.007_bib0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin\u2013paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2013.10.007_bib0070","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.7521","volume":"30","author":"Mitsudomi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"September (9)","key":"10.1016\/j.lungcan.2013.10.007_bib0075","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/JTO.0b013e318260de8b","article-title":"First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study","volume":"7","author":"Maemondo","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"December (36)","key":"10.1016\/j.lungcan.2013.10.007_bib0080","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"January (1)","key":"10.1016\/j.lungcan.2013.10.007_bib0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JOP.2011.000374","article-title":"2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"8","author":"Azzoli","year":"2012","journal-title":"J Oncol Pract"},{"issue":"May (15)","key":"10.1016\/j.lungcan.2013.10.007_bib0090","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1200\/JCO.2010.31.8923","article-title":"American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy","volume":"29","author":"Keedy","year":"2011","journal-title":"J Clin Oncol"},{"issue":"October (6)","key":"10.1016\/j.lungcan.2013.10.007_bib0095","first-page":"456","article-title":"Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors","volume":"37","author":"Giaccone","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"September (3)","key":"10.1016\/j.lungcan.2013.10.007_bib0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.critrevonc.2011.11.010","article-title":"Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence","volume":"83","author":"Ou","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"May (5)","key":"10.1016\/j.lungcan.2013.10.007_bib0105","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol"},{"issue":"August (24)","key":"10.1016\/j.lungcan.2013.10.007_bib0110","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2010.34.0570","article-title":"Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer","volume":"29","author":"Sequist","year":"2011","journal-title":"J Clin Oncol"},{"issue":"December (4)","key":"10.1016\/j.lungcan.2013.10.007_bib0115","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3390\/cancers2042153","article-title":"Targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice","volume":"2","author":"Stabile","year":"2010","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2013.10.007_bib0120","unstructured":"2013. Available at: www.clinicaltrials.gov (accessed 28.02.13)."},{"issue":"September (25)","key":"10.1016\/j.lungcan.2013.10.007_bib0125","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2011.39.3744","article-title":"Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer","volume":"30","author":"Bai","year":"2012","journal-title":"J Clin Oncol"},{"issue":"November (11)","key":"10.1016\/j.lungcan.2013.10.007_bib0130","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/JTO.0b013e31826913f7","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations","volume":"7","author":"Nishie","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"March (3)","key":"10.1016\/j.lungcan.2013.10.007_bib0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.lungcan.2012.11.007","article-title":"Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors","volume":"79","author":"Nishino","year":"2013","journal-title":"Lung Cancer"},{"issue":"September (3)","key":"10.1016\/j.lungcan.2013.10.007_bib0140","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000332758","article-title":"Should epidermal growth factor receptor-tyrosine kinase inhibitor be continued beyond progressive disease?","volume":"4","author":"Kim","year":"2011","journal-title":"Case Rep Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2013.10.007_bib0145","first-page":"S1513","article-title":"Implementation of a national EGFR testing strategy in a publicly funded health system","volume":"6","author":"Ellis","year":"2011","journal-title":"J Thorac Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213004510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213004510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T06:06:16Z","timestamp":1596693976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500213004510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0169500213004510"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.10.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}